Výsledky vyhledávání - "Mark S Hixon"

Akademický článek

Metabolomics-based discovery of diagnostic biomarkers for onchocerciasis.

Autor: Judith R Denery, Ashlee A K Nunes, Mark S Hixon, Tobin J Dickerson, Kim D Janda

Publikováno v: PLoS Neglected Tropical Diseases, Vol 4, Iss 10, p e1000938 (2010)

BACKGROUND: Development of robust, sensitive, and reproducible diagnostic tests for understanding the epidemiology of neglected tropical diseases is an integral aspect of the success of worldwide control and elimination programs. In the treatment of

Externí odkaz: https://doaj.org/article/63c5c57849474d649bc6d31858def5ee

Zobrazit plný text záznamu

Supplementary Data from MET Tyrosine Kinase Inhibition Enhances the Antitumor Efficacy of an HGF Antibody

Autor: Patrick Vincent, Barbara Hibner, Ron de Jong, Hidehisa Iwata, Akio Mizutani, Akira Hori, Kengo Okada, J. David Lawson, Shaosong Chu, Ruhi Kamran, Mark S. Hixon, Shweta Pandya, Deepika Balakrishna, Jennifer Matuszkiewicz, Pamela J. Farrell

Supplemental Table 1. Activity of MET TKIs in enzyme and cellular assessments Supplemental Table 2. Activity of Compound 1 against approximately 130 additional protein kinases. Figure S1. Binding modes of selective MET TKIs. Figure S2. MET TKI, Compo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::120f016d9ddd8b8907dbb9ab603d8673
https://doi.org/10.1158/1535-7163.22504134

Zobrazit plný text záznamu

Data from MET Tyrosine Kinase Inhibition Enhances the Antitumor Efficacy of an HGF Antibody

Receptor tyrosine kinase therapies have proven to be efficacious in specific cancer patient populations; however, a significant limitation of tyrosine kinase inhibitor (TKI) treatment is the emergence of resistance mechanisms leading to a transient,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a781388f16b2563b61d0736ccfdad587
https://doi.org/10.1158/1535-7163.c.6537630

Zobrazit plný text záznamu

Identification of Slow-Binding Inhibitors of the BoNT/A Protease

Autor: Ealin N. Patel, Lewis D. Turner, Mark S. Hixon, Kim D. Janda

Publikováno v: ACS Med Chem Lett

[Image: see text] Botulinum neurotoxin A (BoNT/A) is a lethal toxin, which causes botulism, and is categorized as a bioterrorism threat, which causes flaccid paralysis and death. Botulinum A neurotoxicity is governed through its light chain (LC), a z

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3b7d84138465a7b3bc7b904f6bebe33
https://doi.org/10.1021/acsmedchemlett.2c00028

Zobrazit plný text záznamu

In Silico Development of Combinatorial Therapeutic Approaches Targeting Key Signaling Pathways in Metabolic Syndrome

Autor: Maksim Khotimchenko, Nicholas E. Brunk, Mark S. Hixon, Daniel M. Walden, Hypatia Hou, Kaushik Chakravarty, Jyotika Varshney

Publikováno v: Pharmaceutical research. 39(11)

Dysregulations of key signaling pathways in metabolic syndrome are multifactorial, eventually leading to cardiovascular events. Hyperglycemia in conjunction with dyslipidemia induces insulin resistance and provokes release of proinflammatory cytokine

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::298934da36fb88d263233efb077ec9e8
https://pubmed.ncbi.nlm.nih.gov/35313359

Zobrazit plný text záznamu

A randomized, double-blind, placebo controlled, phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of LB-102, a selective dopamine D

Autor: Lukasz, Biernat, Vincent T, Grattan, Mark S, Hixon, Zachary, Prensky, Andrew R, Vaino

Publikováno v: Psychopharmacology. 239(9)

LB-102 is an N-methylated analogue of amisulpride under development to treat schizophrenia. LB-102 was evaluated in a Phase 1, double-blind, placebo-controlled, clinical study to evaluate safety and pharmacokinetics. This was a first-in-human study e

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::3ce1bbeb9fa60f7e4371147de1793b79
https://pubmed.ncbi.nlm.nih.gov/35841422

Zobrazit plný text záznamu

Combinatorial approaches using an AI/ML-driven drug development platform targeting insulin resistance, lipid dysregulation, and inflammation for the amelioration of metabolic syndrome in patients

Autor: Mark S. Hixon, Maksim Khotimchenko, Kaushik Chakravarty, Hypatia Hou, Daniel M. Walden, Nicholas E. Brunk, Jyotika Varshney

Dysregulations of key signaling pathways leading to metabolic syndrome (MetS) are complex eventually leading to cardiovascular events and type 2 diabetes. Dyslipidemia induces progression of insulin resistance and provokes release of proinflammatory

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::587cb48d41864b3a2429f48dd65fcdd5
https://doi.org/10.1101/2021.09.01.458488

Zobrazit plný text záznamu

Antipsychotic Benzamides Amisulpride and LB-102 Display Polypharmacy as Racemates, S Enantiomers Engage Receptors D2 and D3, while R Enantiomers Engage 5‑HT7

Autor: Zachary Prensky, Andrew R. Vaino, Vincent T. Grattan, Mark S. Hixon

Publikováno v: ACS Omega, Vol 4, Iss 9, Pp 14151-14154 (2019)
ACS Omega

Benzamide antipsychotics such as amisulpride are dosed as racemates though efficacy is assumed to be mediated through S enantiomer binding to D2 receptors. At prescribed doses, the benzamides likely display polypharmacy since brain exposure should be

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d18ee55cecf568325adfa01d19153672
https://doaj.org/article/60aaa2900e364064a33e7ab458891010

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání